BioCatalyst

TILT-123, pembrolizumab, pegylated liposomal doxorubicin — catalyst calendar

1 verified catalyst event(s) referencing TILT-123, pembrolizumab, pegylated liposomal doxorubicin, each linked to its official source. Verified as of 2026-11-02.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pe
Phase 1/2 · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
 TILT Biotherapeutics Ltd. TILT-123, pembrolizumab, pegylated lipos ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.